Osteogenic Capacity and Mettl14 and Notch1 Expression of Adipose-Derived Stem Cells from Osteoporotic Rats

FENG Mao-geng, YANG Shuang-lin, LUO Dao-wen, PENG Shuang-lin, LOU Fang-zhi, XIAO Jin-gang

Abstract

To investigate the differences in the osteogenic capacity of osteoporotic adipose-derived stem cells (OP-ASCs) and normal control adipose-derived stem cells (Ctrl-ASCs), and to examine the expression levels of RNA methyltransferase like 14 (Mettl14) and the Notch signaling molecule 1 (Notch1).  Methods  The osteoporosis (OP) model of SD rats was established with ovariectomy (OVX). Micro-CT, HE staining and Masson staining were performed to identify the successful establishment of the OP model, OP-ASCs and Ctrl-ASCs were isolated and cultured adherently. Then, the three-way differentiation capacity of the adipose-derived stem cells (ASCs) was determined through alizarin red staining, alcian blue staining and oil red O staining and flow cytometry was conducted to examine the surface antigens CD29, CD44, CD90, CD31, CD34, and CD45. Alizarin red staining and comparison of the mRNA and protein expression of Run-related transcription factor 2 (Runx2) were done to explore the differences in osteogenic potential of OP-ASCs and Ctrl-ASCs. Real-time PCR and Western blot were performed to explore the expression differences of Mettl14 and Notch1 at mRNA and protein levels between OP-ASCs and Ctrl-ASCs.  Results  Micro-CT, HE and Masson staining results showed that the number of trabecular bone decreased and the spacing increased in the tibias of the osteoporosis group (OP group) compared with those of the control group (Ctrl group), indicating that the OP model was established successfully. Three-way differentiation and flow cytometry results confirmed the successful isolation and culture of ASCs. After osteogenic induction, alizarin red staining showed that OP-ASCs had fewer number and more scattered distribution of mineralized nodules than Ctrl-ASCs did. The expression of Runx2 in OP-ASCs was lower than that in Ctrl-ASCs (P<0.05). Mettl14 as well as Notch1 showed lower expression in OP-ASCs than they did in Ctrl-ASCs (P<0.05).  Conclusion  The osteogenic capacity of OP-ASCs was lower compared with that of Ctrl-ASCs, Mettl14 expression of OP-ASCs was decreased compared with that of Ctrl-ASCs, and the Notch signaling pathway was inhibited in OP-ASCs. The study helps build the foundation for further investigation in the specific mechanisms of Mettl14 and Notch1 during osteogenic differentiation of OP-ASCs.

 

Keywords: Osteoporotic rat, Adipose-derived stem cells, Osteogenic differentiation, RNA methylation, Mettl14, Notch signaling pathway

 

Full Text:

PDF


References


LI W， HOU S， YU B， et al. Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum Genet，2010，127(3): 249–285.

GENANT H， COOPER C， POOR G， et al. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int，1999，10(4): 259–264.

CHEN X J， HUA W F， HUANG X， et al. Regulatory role of RNA N6-methyladenosine modification in bone biology and osteoporosis. Front Endocrinol (Lausanne)，2019，10: 911[2021-04-15]. https://doi.org/ 10.3389/fendo.2019.00911.

YAN G， YUAN Y， HE M， et al. m6A methylation of precursor-miR-320/RUNX2 controls osteogenic potential of bone marrow-derived mesenchymal stem cells. Mol Ther Nucleic Acids，2020，19: 421–436.

ZHANG Q， RIDDLE R， YANG Q， et al. The RNA demethylase FTO is required for maintenance of bone mass and functions to protect osteoblasts from genotoxic damage. Proc Natl Acad Sci U S A，2019， 116(36): 17980–17989.

BOKAR J， SHAMBAUGH M， POLAYES D， et al. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA，1997，3(11): 1233–1247.

LIU J， YUE Y， HAN D， et al. A Mettl3-Mettl14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol， 2014，10(2): 93–95.

LEE S Y， LONG F X. Notch signaling suppresses glucose metabolism in mesenchymal progenitors to restrict osteoblast differentiation. J Clin Invest，2018，128(12): 5573–5586.

WESTIN J. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk，2014，14(5): 335–342.

BALDRIDGE D， SHCHELOCHKOV O， KELLEY B， et al. Signaling pathways in human skeletal dysplasias. Annu Rev Genomics Hum Genet， 2010，11: 189–217.

YINGLING V， MITCHELL K， LUNNY M. Acute hypothalamic suppression significantly affects trabecular bone but not cortical bone following recovery and ovariectomy surgery in a rat model. Peer J，2016， 12(4): 1575–1595.

LIU Z， LIANG W， KANG D， et al. Increased osteoblastic Cxcl9 contributes to the uncoupled bone formation and resorption in postmenopausal osteoporosis. Clin Interv Aging，2020，15: 1201–1212.

WU T， SUN J， TAN L， et al. Enhanced osteogenesis and therapy of osteoporosis using simvastatin loaded hybrid system. Bioact Mater，2020， 5(2): 348–357.

BRENNAN O， SWEENEY J， O’MEARA B， et al. A natural, calcium-rich marine multi-mineral complex preserves bone structure, composition and strength in an ovariectomised rat model of osteoporosis. Calcif Tissue Int，2017，101(4): 445–455.

RIANCHO J， OLMOS J， PINEDA B， et al. Wnt receptors, bone mass, and fractures: gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication. Eur J Endocrinol，2011，164(1): 123–131.

CHEN H， LEE M， CHEN C， et al. Proliferation and differentiation potential of human adipose‐derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med，2012，16(3): 582–593.

WANG L， HUANG C， LI Q， et al. Osteogenic differentiation potential of adipose‐derived stem cells from ovariectomized mice. Cell Prolif， 2017，50(2): e12328[2021-04-15]. https://doi.org/10.1111/cpr.12328.

JAVED A， AFZAL F， BAE J S， et al. Specific residues of Runx2 are obligatory for formation of BMP2-induced Runx2-SMAD complex to promote osteoblast differentiation. Cells Tissues Organs，2009， 189(1/2/3/4): 133–137.

YIN Q， WANG J， FU Q， et al. CircRUNX2 through has-miR-203 regulates RUNX2 to prevent osteoporosis. J Cell Mol Med，2018，22(12): 6112–6121.

ZHANG C X， CHEN Y S， SUN B F， et al. m6A modulates haematopoietic stem and progenitor cell specification. Nature，2017， 549(7671): 273–276.

DOMINISSINI D， MOSHITCH-MOSHKOVITZ S， SCHWARTZ S， et al. Topology of the human and mouse m6A RNA methylomes revealed by m6Aseq. Nature，2012，485(7397): 201–206.

MEYER K， SALETORE Y， ZUMBO P， et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell，2012，149(7): 1635–1646.

CARROLL S， NARAYAN P， ROTTMAN F. N6-methyladenosine residues in an intron-specific region of prolactin pre-mRNA. Mol Cell Biol，1990，10(9): 4456–4465.

TIAN C， HUANG Y L， LI Q M， et al. Mettl3 regulates osteogenic differentiation and alternative splicing of vegfa in bone marrow mesenchymal stem cells. Int J Mol Sci，2019，20(3): 551[2021-04-15]. https://doi.org/10.3390/ijms20030551.

WU Y， XIE L， WANG M， et al. Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and steoporosis. Nat Commun，2018，9(1): 4772[2021-04-15]. https://doi.org/10.1038/s41467-018-06898-4.

BRAY S. Notch signalling in context. Nat Rev Mol Cell Biol，2016，17(11): 722–735.

WEI C X， PHANG C W， JIAO R J. Epigenetic regulation of Notch signaling during drosophila development. Adv Exp Med Biol，2020，1218: 59–75.

MASHANOV V， AKIONA J， KHOURY M， et al. Active Notch signaling is required for arm regeneration in a brittle star. PLoS One， 2020，15(5): e0232981[2021-04-15]. https://doi.org/10.1371/journal.pone.0232981.

GU C H， WANG Z Y， ZHOU N C， et al. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1. Mol Cancer，2019，18(1): 168[2021-04-15]. https://doi.org/ 10.1186/s12943-019-1084-1.


Refbacks

  • There are currently no refbacks.